CINCINNATI -- (BUSINESS WIRE) -- Ken Phelps, one of the nation’s leading experts in the 505(b)(2) development pathway, will be a keynote speaker at the EPPIC Annual Conference in San Francisco, January 6.
Titled “Repurposing of Drugs,” his speech will look at opportunities that sponsors have to develop niche products that can be developed with dramatically lower costs using the 505(b)(2) pathway to FDA approval.
“A 505(b)(2) non-disclosure agreement may also be eligible for significant market exclusivity, depending on how it’s developed,” said Phelps, president and CEO of Camargo Pharmaceutical Services. “That’s a potential breakaway marketing advantage that could be valuable to a lot of companies.”
EPPIC was formed in 1998 by San Francisco Bay Area pharmaceutical and biotechnology professionals to promote networking, create US-India life science synergy and function as a resource for industry and academia. This year’s Annual Conference is titled “New Frontiers in Health Care Sciences” and will be held from 8 a.m. to 7:30 p.m. Sunday, January 6, at the Westin San Francisco Airport.
Phelps will also be hosting a webinar on 505(b)(2) for the Pharmaceutical Education and Research Institute (PERI) titled “Fast and Cost-Effective Drug Approval” December 13 from 3 to 4 p.m. EST. PERI is an independent nonprofit dedicated to providing scientific and technical continuing education for the pharmaceutical, biotechnology and medical device industry. Visit http://peri.org/event-registration/?ee=53 to register.
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is your full-service drug development partner specializing in the 505(b)(2) process. Before development even begins, we verify profit potential by working with your team to develop a comprehensive program and timeline complete with important milestones and cost objectives. We manage every facet of the plan throughout your development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission. Connect with Camargo on LinkedIn, the President’s blog or visit www.camargopharma.com for more information.